These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Now that we know what's BeSt, what is good value for the money? Bansback N; Marra CA Arthritis Rheum; 2009 Mar; 61(3):289-90. PubMed ID: 19248126 [No Abstract] [Full Text] [Related]
4. The economics of treatment in early rheumatoid arthritis. Bansback N; Marra CA; Finckh A; Anis A Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):83-92. PubMed ID: 19233048 [TBL] [Abstract][Full Text] [Related]
5. Report of the OMERACT task force on economic evaluation. Outcome Measures in Rheumatology. Gabriel S; Tugwell P; O'Brien B; Yelin E; Drummond M; Ruff B; Brooks P; Bombardier C; Boers M J Rheumatol; 1999 Jan; 26(1):203-6. PubMed ID: 9918264 [No Abstract] [Full Text] [Related]
6. [Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists]. Kulp W; Greiner W; Graf von der Schulenburg JM Pharm Unserer Zeit; 2003; 32(5):420-5. PubMed ID: 14526463 [No Abstract] [Full Text] [Related]
7. Cost-effectiveness analysis: out of touch with clinical reality? Maetzel A Arthritis Rheum; 2005 Feb; 53(1):3-4. PubMed ID: 15696549 [No Abstract] [Full Text] [Related]
8. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years. Sany J; Cohen JD; Combescure C; Bozonnat MC; Roch-Bras F; Lafon G; Daurès JP Rheumatology (Oxford); 2009 Oct; 48(10):1236-41. PubMed ID: 19620209 [TBL] [Abstract][Full Text] [Related]
9. Challenges in economic evaluation of new drugs: experience with rituximab in Hungary. Brodszky V; Orlewska E; Pentek M; Karpati K; Skoupa J; Gulacsi L Med Sci Monit; 2010 Jan; 16(1):SR1-5. PubMed ID: 20037504 [TBL] [Abstract][Full Text] [Related]
10. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden. Lindgren P; Geborek P; Kobelt G Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709 [TBL] [Abstract][Full Text] [Related]
11. Health economics: implications for novel antirheumatic therapies. Kavanaugh A Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv65-9. PubMed ID: 16239392 [TBL] [Abstract][Full Text] [Related]
12. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Lundkvist J; Kastäng F; Kobelt G Eur J Health Econ; 2008 Jan; 8 Suppl 2():S49-60. PubMed ID: 18157732 [TBL] [Abstract][Full Text] [Related]
13. The pharmacoeconomics of newer therapeutics for rheumatic diseases. Kavanaugh A Rheum Dis Clin North Am; 2006 Feb; 32(1):45-56, viii. PubMed ID: 16504820 [TBL] [Abstract][Full Text] [Related]
14. The cost-utility analysis of the BeSt trial: is a camel in fact a horse with abnormalities in the distribution of dorsal fat? Comment on the article by van den Hout et al. Boers M Arthritis Rheum; 2009 Nov; 61(11):1616-7; author reply 1617-8. PubMed ID: 19877096 [No Abstract] [Full Text] [Related]
15. PHARMAC responds on TNF inhibitors for inflammatory arthritis. Metcalfe S; Moodie P; Grocott R; Wilkinson T N Z Med J; 2005 Dec; 118(1227):U1799. PubMed ID: 16372039 [No Abstract] [Full Text] [Related]
16. Subcutaneous methotrexate to cut costs? Hassanzadeh R; Mangan C; France J; Bawa S J Rheumatol; 2012 Aug; 39(8):1764-5. PubMed ID: 22859538 [No Abstract] [Full Text] [Related]